Preventing Adverse Cardiac Events in COPD

Cardiovascular Diseases Clinical Trial

Official title:

Preventing Adverse Cardiac Events in Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03917914
• Other study ID #: PACE in COPD
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: June 30, 2020
• Est. completion date: March 2025

Study information

• Verified date: January 2024
• Source: The George Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A double-blind, randomised controlled trial in participants with COPD to assess the efficacy of proactive treatment of cardiac risk in people with COPD. We hypothesise that treating known and undiagnosed CVD in COPD participants will improve both cardiac and respiratory outcomes.

Description:

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of global health-related morbidity and mortality. Heart disease in COPD is a known but neglected comorbidity and cardiovascular disease (CVD) accounts for 30-50% of deaths in COPD participants. Studies repeatedly show that CVD in COPD participants is under-recognised and under-treated yet participants with COPD are frequently excluded from clinical trials of drugs which reduce cardiac morbidity and mortality. This has led to under-treatment of CVD in COPD participants. A particular concern is low use of β-blockers. These have previously been considered to be contra-indicated in COPD and no RCTs have been conducted in this population. There is now observational evidence that cardioselective β-blockers are safe and may improve mortality, but this data is limited to retrospective analyses of cohorts of COPD participants. Contrary to previous concerns, retrospective analyses also suggest that cardioselective β-blockers may reduce the risk of COPD exacerbations. The proposed study will focus on treating CVD in COPD participants to reduce mortality and morbidity. The study will be conducted in approximately 20 sites in Australia and New Zealand, and possibly 1-2 international sites. Participants with COPD will be randomised to one of two treatment arms in addition to receiving usual care for their COPD over the study duration of 24 months.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 280
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

Participants will be eligible for this study if they qualify on all of the following:

1. Have provided written informed consent

2. Have COPD defined by the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria

3. Aged 40-85 years

4. FEV1 =30% and =70% predicted post-bronchodilator

5. FEV1/FVC <0.7 post-bronchodilator

6. Have had a COPD exacerbation in the previous 24 months requiring oral corticosteroid, antibiotics, or both

7. If taking maintenance OCS, dosage is stable and =10mg daily for 4 weeks prior to randomisation

8. Resting SBP =100mmHg

9. SBP and spirometry criteria must be met after the test dose of bisoprolol of 1.25mg

10. (New Zealand only) A history of cardiovascular disease, including heart failure, ischaemic heart disease, tachyarrhythmias, and hypertension Exclusion Criteria:

Participants will be ineligible for the study if they have any of the following:

1. Concurrent therapy with any other ß-blocker

2. Resting HR <60bpm

3. Unstable left HF (i.e. symptomatic and/or necessary change in management in the last 12 weeks, or in clinicians' opinion)

4. Clinically significant pulmonary hypertension, which in the investigator's opinion would be a contraindication for ß-blocker therapy

5. Severe end-stage peripheral vascular disease

6. 2nd or 3rd degree heart block

7. Currently using or have been prescribed LTOT or resting saturated oxygen level <90% when stable

8. Expected survival is less than 12 months, or in the investigator's opinion, the person has such unstable disease (of any type) that maintaining 12 months' participation would be unlikely

9. Clinical instability since a MACE in the previous 12 weeks

10. Lower respiratory tract infection or AECOPD within the last 8 weeks

11. COPD not clinically stable as determined by the investigator

12. In the clinician's view, have asthma-COPD overlap or co-existent asthma are present; or an improvement in FEV1 =400mL post-bronchodilator is observed on two occasions

13. Females of child-bearing age and capability who are pregnant or breastfeeding or those in this group not using adequate birth control

14. Coexistent illness which precludes participation in the study (poorly controlled diabetes, active malignancy)

15. Severe end-stage liver disease defined by INR>1.3 and albumin<30g/L or portal hypertension/ascites

16. High chance in the view of the treating physician that the potential participant will not adhere to study requirements

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Bisoprolol
As in arm description
• Placebo Oral Tablet
As in arm description

Locations

Country	Name	City	State
Australia	Prince Charles Hospital	Brisbane	Queensland
Australia	Princess Alexandra Hospital	Brisbane	Queensland
Australia	Campbelltown Hospital	Campbelltown	New South Wales
Australia	Liverpool Hospital	Liverpool	New South Wales
Australia	Fiona Stanley Hospital	Murdoch	Western Australia
Australia	John Hunter Hospital & Hunter Medical Research Institute	Newcastle	New South Wales
Australia	Institute for Respiratory Health	Perth	Western Australia
Australia	TrialsWest Pty Ltd	Perth	Western Australia
Australia	Gold Coast University Hospital	Southport	Queensland
Australia	Concord Repatriation General Hospital	Sydney	New South Wales
Australia	Westmead Hospital	Sydney	New South Wales
New Zealand	Greenlane Clinical Centre, Auckland District Health Board	Auckland
New Zealand	Middlemore Hospital	Auckland
New Zealand	University of Otago	Christchurch
New Zealand	Dunedin Hospital	Dunedin
New Zealand	Waikato Hospital	Hamilton
New Zealand	Medical Research Institute of New Zealand	Wellington

Sponsors (1)

Lead Sponsor	Collaborator
The George Institute

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality	Composite outcome of the following that will be analysed using a win-ratio apprach according to clinical importance	Baseline to 24 months
Primary	Hospitalisation for COPD exacerbation		Baseline to 24 months
Primary	Hospitalisation for primary cardiac cause (ischaemia, arrhythmia, heart failure or ischaemic stroke)		Baseline to 24 months
Primary	Moderate COPD exacerbation - not hospitalised by treated with oral corticosteroids/antibiotics or both		Baseline to 24 months
Primary	Cardiac Hospitalisation for cardiac cause other than ischemia, arrythmia or heart failure		Baseline to 24 months
Primary	Respiratory hospitalisation for a respiratory cause other than COPD exacerbation		Baseline to 24 months
Primary	Decrease in FEV1 or greatest FEV1% drop - largest decrease in FEV1 from post-bronchodiliator spirometry at baseline		Baseline to 24 months
Primary	Mild COPD exacerbation - treated with increased inhalers/inhaler technique/addition of theophylline		Baseline to 24 months
Primary	Higher SGRQ score (clinically important change >= 4)		Baseline to 12 and 24 months
Primary	Higher CAT score (clinically important change >= 2)		Baseline to 12 and 24 months
Secondary	Time to first moderate-severe COPD Exacerbation		Baseline to 24 months
Secondary	Severe (hospital admission) COPD exacerbation rate (annualised)		Baseline to 24 months
Secondary	Number of events of composite (annualised) cardio-respiratory hospital admissions and MACE		Baseline to 24 months
Secondary	Quality of life assessed by St George's Respiratory Questionnaire (SGRQ)	The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in patients with diseases of airways obstruction.; Scores are calculated for three domains: Symptoms, Activity and Impacts (Psycho-social) as well as a total score.; Psychometric testing has demonstrated its repeatability, reliability and validity. Sensitivity has been demonstrated in clinical trials.; A minimum change in score of 4 units was established as clinically relevant after patient and clinician testing. The SGRQ has been used in a range of disease groups including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis, and in a range of settings such as randomised controlled therapy trials and population surveys.	Baseline to 24 months
Secondary	EuroQoL Group 5-5 Dimension self-report questionnaire (EQ-5D-5L) to assess health state utilities	EQ-5D-5L consists of 2pg: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).; Five dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression.; Each dimension 5 levels: no problems, slight problems, moderate problems, severe problems, extreme problems.; Patient indicates their health state by ticking most appropriate statement in each of the five dimensions.; This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.; EQ VAS records patient's self-rated health on a vertical visual analogue scale. Endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.	Baseline to 24 months
Secondary	Healthcare utilisation costs and Quality Adjusted Life Years (QALYs) evaluation of the treatment intervention	Mean differences in healthcare utilisation costs and Quality Adjusted Life Years between both treatment groups will be estimated.; Costs will be ascertained from participants and study records. Health care utilisation will be on the basis of self-reported GP and hospital attendances and changes in concomitant medication. Health state utilities will be estimated via the EQ-5D-5L and will be used to weight survival up to 24 months to determine Quality Adjusted Life Years.	Baseline to 24 months
Secondary	Health status assessed by COPD Assessment Test (CAT)		Baseline to 24 months
Secondary	Clinic spirometry: post-bronchodilator FEV1 (Forced Expiratory Volume) (L)		Baseline to 24 months
Secondary	Clinic spirometry: % predicted post-bronchodilator		Baseline to 24 months
Secondary	Hospital admissions for all respiratory causes		Baseline to 24 months
Secondary	Hospital admissions for all cardiac causes	All cardiac causes includes ischaemia, arrhythmia, heart failure, acute arrhythmia, non-ST-elevation myocardial infarction, urgent revascularisation (stent/angioplasty/coronary artery bypass grafting), and MACE events (includes myocardial infarction, sudden death, cardiac death or a fatal event in system organ classes for cardiac and vascular disorders, and serious and non-serious stroke).	Baseline to 24 months
Secondary	Total Number of cardiac events: MACE plus acute arrhythmia, Non-ST-elevation myocardial infarction (NSTEMI), urgent revascularisation (stent/angioplasty/Coronary artery bypass grafting [CABGs]) and clinically diagnosed heart failure episodes.		Baseline to 24 months
Secondary	Time to a composite outcome (includes any) of: all-case mortality; hospitalisation for COPD exacerbation, hospitalisation for primary cardiac cause (arrytmmia, ischaemia or heart failure) or MACE		Baseline to 24 months
Secondary	COPD exacerbation rate (annualised)		Baseline to 24 months